VitalHub Corp. (TSX: VHI) said on July 13, 2026 that it had bought Buddy Healthcare Ltd Oy, a Finnish care coordination platform, for total up-front consideration of 8.6 million euros plus an earnout of up to 4.5 million euros. The Toronto software company, which also trades on the OTCQX under VHIBF, described the deal as a beachhead in the Nordic healthcare market. The purchase closed on July 10, 2026, three days before the announcement, and the terms disclosed in VitalHub’s second quarter filings three weeks later fill in details the press release left out.

Terms as announced

The price paid at closing was a cash payment of 8.3 million euros, subject to working capital adjustments, plus 75,000 VitalHub common shares. The earnout is all cash, capped at 4.5 million euros, and is tied to performance targets measured at the end of the first two calendar years after the acquisition. VitalHub did not disclose how those targets are defined.

Buddy Healthcare was established in 2016 and sells a platform that digitises specialised care pathways, replacing physical notes, telephone calls and unnecessary visits with automated guidance. It consists of a web application for clinicians and a mobile application for patients, and the company describes it as compliant with the European Union’s medical device rules at Class IIa, covering perioperative and secondary care pathways. As at June 30, 2026 it had annual recurring revenue of approximately 2.8 million euros and was approximately breakeven on an adjusted EBITDA basis. Its customers sit across Europe, including Finland and the United Kingdom.

Chief executive Dan Matlow said the platform helps hospitals “digitize and automate complex care digital pathways across over 23 specialties”, and that the medical device registration is itself evidence of the workflow complexity involved. Buddy Healthcare’s founder and chief executive, Jussi Määttä, said the business had built “a leading care pathway management platform trusted by hospitals across Europe to improve patient preparation, engagement, and recovery”.

What the quarterly filing added

VitalHub reported second quarter results on August 6, 2026 and restated the transaction in accounting terms. It put total closing consideration at approximately $13.4 million Canadian, equal to the 8.3 million euros in cash, subject to post-closing working capital adjustments and to a 10% escrow held for nine months, together with the 75,000 shares. The escrow was first disclosed in the August filing rather than in the July release. It is a routine protection for a buyer against warranty claims, and it means a tenth of the cash price is not finally settled until the spring.

The same filing set the deal against the group. VitalHub’s annual recurring revenue was $101,533,157 at June 30, 2026, up from $79,589,081 a year earlier, an increase of $21,944,076 or 28%. That growth broke down into organic growth of $8,124,613 or 10%, acquisition growth of $12,000,000 or 15%, and a gain of $1,819,463 from currency movement. Including Buddy Healthcare, pro forma recurring revenue as at June 30, 2026 would have been approximately $106.0 million.

Quarterly revenue was $31,737,512 against $23,857,548, up 33%. Gross profit margin declined to 79% from 81%. Adjusted EBITDA was $8,162,917, or 26% of revenue, matching the prior year margin on a 29% increase in the absolute figure. Net income before income taxes was $3,644,002 against $2,255,226. For the six months, revenue was $63,643,914 against $45,532,514 and adjusted EBITDA was $16,152,678, or 25% of revenue, against 26% a year earlier. Cash and short-term investments stood at $136,508,574 at June 30, 2026, up from $119,180,625 at December 31, 2025. Deferred revenue, the clearest balance-sheet signal of contracted work still to be recognised, rose to $61,042,705 from $45,434,654 a year earlier, and the group described itself as serving more than 1,300 clients with over 700 employees globally.

Analysis: a capability purchase priced like an option

Measured against VitalHub’s own numbers, Buddy Healthcare is small. The target’s 2.8 million euros of recurring revenue sits against a group figure above one hundred million Canadian dollars, and the pro forma line of approximately $106.0 million is the clearest statement of the increment. Put differently, the acquisition adds roughly what the group’s organic growth produced over the preceding twelve months, which was $8,124,613. An increment of that size does not change the scale of the group. What it buys is a product category VitalHub says it did not have, a regulatory registration, a Finnish engineering team and a Nordic entity through which to sell the rest of the suite.

The structure tells the same story. The earnout of up to 4.5 million euros is more than half the up-front cash, all of it payable only on targets measured at the end of the first two calendar years. That structure leaves more than half of the up-front cash value contingent on results measured after closing rather than fixed at closing. It also means the true cost of the acquisition is unknown until the end of the second year, and that VitalHub’s reported consideration will move if the accrual for contingent payments changes. A reader tracking the price paid should follow that line in the financial statements rather than the July headline.

The margin arithmetic deserves attention too. Buddy Healthcare is described as approximately breakeven on adjusted EBITDA, while VitalHub runs at 26% of revenue. Absorbing a breakeven asset does not help the consolidated margin, and the group is already showing a small downward drift, with gross margin at 79% against 81% and six-month adjusted EBITDA margin at 25% against 26%. VitalHub’s stated case is that Buddy Healthcare’s growth accelerates on its United Kingdom customer base, which would fix the margin question over time. That case is untested and no revenue target has been made public.

One more line in the ARR bridge is worth isolating. Of the $21,944,076 increase in recurring revenue over the year, $1,819,463 came from foreign exchange movement, and $651,853 of the $2,454,348 quarterly increase did as well. VitalHub reports in Canadian dollars while earning in sterling and now in euros. A meaningful slice of reported recurring revenue growth is currency translation rather than customers, and adding a euro-denominated business increases that sensitivity.

Capital allocation

On the same day it reported second quarter results, VitalHub said the Toronto Stock Exchange had accepted its notice for a normal course issuer bid to buy back up to 3,170,708 shares over the twelve months from August 11, 2026 to August 10, 2027. That is approximately 4.99% of the 63,414,163 shares outstanding as at July 28, 2026. Average daily trading volume over the prior six months was 359,640 shares, capping daily purchases at 89,910. All repurchased shares are to be cancelled, funded from working capital.

That puts the company buying its own stock and buying companies from the same balance sheet, which held $136,508,574 in cash and short-term investments at the end of June, and issuing 75,000 shares as part of the Buddy Healthcare price while planning to retire up to forty times that number.

What to watch

The third quarter report is the first that will consolidate Buddy Healthcare. The lines to read are the acquisition component of the recurring revenue bridge, the gross margin, and any disclosure of the contingent consideration liability, which is where the earnout will first become visible. VitalHub has not disclosed Buddy Healthcare’s customer count, the split of its revenue between Finland and the United Kingdom, or an integration cost estimate, and none of those are required to be disclosed separately for an acquisition of this size.